While caution is warranted in extrapolating these results to humans, our results suggest that the brain distribution of clinically used ABCB1/ABCG2 substrate drugs may be unaffected by possible disease-induced alterations in transporter abundances at the BBB of AD patients. The gene discussed is ABCB1; the disease is Alzheimer disease.